The Prognostic Significance of Lymphocyte-C-Reactive Protein Ratio in Non-Small Cell Lung Cancer Patien Receiving Immunotherapy

Abstract

Objectives: In this study, the significance of lymphocyte-C-reactive protein ratio (LCR) in indicating the prognosis/clini-cal course of patients with non-small cell lung cancer receiving immunotherapy was investigated. Methods: All patients with non-small cell lung cancer who applied to Samsun Medicalpark Medical Oncology outpatient clinic between January 2020 and September 2022 and who received immunotherapy treatments after chemotherapy were included in this retrospective study. Total of 57 patients were included in this retrospective analysis. Clinical data of patients were recorded from patient files. Results: This study was conducted with 57 patients with stage IV non-small cell lung cancer who received immunotherapy after failing to respond chemotherapy. The white blood cell, neutrophil, lymphocyte, monocyte and platelet counts of the patients who responded to the immunotherapy treatment significantly decreased after the treatment. When the pre-treatment values of patients who responded to and did not respond to immunotherapy were compared, pre-treatment white blood cell, neutrophil, C-reactive protein (CRP) and platelet to lymphocyte ratio (PLR) values were significantly higher in patients who did not respond to treatment. Pre-treatment serum albumin and LCR values were significantly higher in patients who respondedto immunotherapy. Conclusion: This study demonstrated that higher LCR values before receiving immunotherapy may be a positive prognosis indicator in stage IV non-small lung cancer patients.